Since the introduction of EMA’s Clinical Data Publication Policy, sponsors have been grappling with a unique problem – the timely and accurate capture and protection of personal and commercial data contained in clinical trial documents. As this information is often dense, varied, and buried in lengthy unstructured text, its post-hoc protection through redaction or statistically derived transformation can pose a significant challenge.
As public document disclosure becomes an integral part of the clinical trial lifecycle, sponsors can proactively reduce this burden by incorporating best practices in writing transparency-friendly clinical documents.
Join Abby McDonell, Sr. Program Manager with IQVIA’s Clinical Trial Transparency Team (powered by Privacy Analytics), to gain actionable insights on optimising your medical writing processes to simplify downstream disclosure and transparency initiatives while ensuring participant and commercial data privacy remains protected.